Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Mycophenolic Acid 25fludarabine phosphate 21Whole-Body Irradiation 21Cyclophosphamide 21Cyclosporine 16Tacrolimus 15Peripheral Blood Stem Cell Transplantation 15Busulfan 14fludarabine 11Cord Blood Stem Cell Transplantation 9Methotrexate 8Melphalan 8Granulocyte Colony-Stimulating Factor 8Cytarabine 8Antilymphocyte Serum 8Filgrastim 7Thiotepa 6Etoposide 6sargramostim 4merphos 4Radiotherapy 4Drug Therapy 4Cyclosporins 4Azacitidine 4thymoglobulin 3Vorinostat 3Sirolimus 3Lenalidomide 3Idarubicin 3tipifarnib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Anemia, Refractory, with Excess of Blasts × lintuzumab × Clear all
NCT00997243 2017-05-10

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡